{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:36:16Z","timestamp":1791246976684,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Government of Japan Ministry of Health Labour and Welfare","doi-asserted-by":"publisher","award":["JPMH23FF1002"],"award-info":[{"award-number":["JPMH23FF1002"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.coi.2025.102662","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:26:48Z","timestamp":1758587208000},"page":"102662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Post-transplant cyclophosphamide for\u00a0graft-versus-host disease prophylaxis: current status and optimization strategies"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5118-7950","authenticated-orcid":false,"given":"Shigeo","family":"Fuji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ohmoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102662_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101286","article-title":"Haploidentical transplantation: an optimal platform for graft manipulation and cellular therapies","volume":"72","author":"Astigarraga","year":"2025","journal-title":"Blood Rev"},{"key":"10.1016\/j.coi.2025.102662_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2025.102662_sbref3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.coi.2025.102662_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.101034","article-title":"The development of post-transplant cyclophosphamide: half a century of translational team science","volume":"62","author":"O'Donnell","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.coi.2025.102662_bib5","unstructured":"CIBMTR database summary slides; 2024. \u3008https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fcibmtr.org%2FFiles%2FSummary-Slides--Reports%2FCIBMTR-Summary-Slides-2024\u20135.12.2025-WEB.pptx&wdOrigin=BROWSELINK\u3009."},{"key":"10.1016\/j.coi.2025.102662_bib6","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3324\/haematol.2022.281256","article-title":"Post-transplant cyclophosphamide: overcoming the HLA barrier to hematopoietic stem cell transplants","volume":"107","author":"Bacigalupo","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.coi.2025.102662_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern approaches to HLA-haploidentical blood or marrow transplantation","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.coi.2025.102662_sbref7","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bjh.19228","article-title":"Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation","volume":"204","author":"Fuji","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coi.2025.102662_bib9","doi-asserted-by":"crossref","first-page":"328.e1","DOI":"10.1016\/j.jtct.2021.01.007","article-title":"Multicenter Phase II study on haploidentical bone marrow transplantation using a reduced-intensity conditioning regimen and posttransplantation cyclophosphamide in patients with poor-prognosis lymphomas","volume":"27","author":"Castagna","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.coi.2025.102662_bib10","doi-asserted-by":"crossref","first-page":"928.e1","DOI":"10.1016\/j.jtct.2021.07.010","article-title":"A Phase I\/II multicenter trial of HLA-haploidentical PBSCT with PTCy for aggressive adult T cell Leukemia\/Lymphoma","volume":"27","author":"Tanaka","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.coi.2025.102662_bib11","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1182\/bloodadvances.2022007264","article-title":"Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide","volume":"6","author":"Al Malki","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2025.102662_bib12","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/bloodadvances.2020001648","article-title":"Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults","volume":"4","author":"Symons","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2025.102662_bib13","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","volume":"18","author":"Solomon","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.coi.2025.102662_bib14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41409-018-0279-1","article-title":"Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide","volume":"54","author":"Sugita","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.coi.2025.102662_bib15","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2015.06.008","article-title":"HLA-Haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide after busulfan-containing reduced-intensity conditioning","volume":"21","author":"Sugita","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.coi.2025.102662_bib16","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41409-020-01065-0","article-title":"Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation","volume":"56","author":"Sugita","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.coi.2025.102662_bib17","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41409-019-0594-1","article-title":"Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients","volume":"54","author":"Bacigalupo","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.coi.2025.102662_bib18","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.2020007535","article-title":"Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial","volume":"137","author":"Fuchs","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102662_bib19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2019.10.014","article-title":"Prospective randomized study comparing myeloablative unrelated umbilical cord blood transplantation versus HLA-haploidentical related stem cell transplantation for adults with hematologic malignancies","volume":"26","author":"Sanz","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.coi.2025.102662_bib20","doi-asserted-by":"crossref","first-page":"109.e1","DOI":"10.1016\/j.jtct.2021.11.002","article-title":"Umbilical cord blood or HLA-haploidentical transplantation: real-world outcomes versus randomized trial outcomes","volume":"28","author":"O'Donnell","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.coi.2025.102662_bib21","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1111\/bjh.19372","article-title":"First complete remission favours haploidentical haematopoietic stem cell transplantation with post-transplant cyclophosphamide over cord blood transplantation in acute lymphoblastic leukaemia","volume":"204","author":"Jo","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coi.2025.102662_sbref21","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102662_sbref22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa2503189","article-title":"Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin","volume":"393","author":"Curtis","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102662_bib24","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coi.2025.102662_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-00990-3","volume":"14","author":"Brissot","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.coi.2025.102662_bib26","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00277-016-2654-6","article-title":"The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT)","volume":"95","author":"Ishida","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.coi.2025.102662_bib27","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41409-022-01908-y","article-title":"Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies","volume":"58","author":"Dul\u00e9ry","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl","key":"10.1016\/j.coi.2025.102662_bib28","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtct.2023.12.021","article-title":"Interim results of a phase I\/II trial of intermediate-dose post-transplantation cyclophosphamide after reduced intensity conditioned HLA-mismatched bone marrow transplantation for older or unfit patients","volume":"30","author":"McCurdy","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"Suppl\u00a01","key":"10.1016\/j.coi.2025.102662_bib29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood-2021-146997","article-title":"Phase I\/II study of reduced dosing of post-transplantation cyclophosphamide (PTCy) after HLA-haploidentical bone marrow transplantation","volume":"138","author":"McAdams","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102662_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101080","article-title":"Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies","volume":"62","author":"Dul\u00e9ry","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.coi.2025.102662_bib31","doi-asserted-by":"crossref","first-page":"587.e1","DOI":"10.1016\/j.jtct.2022.06.006","volume":"28","author":"Battipaglia","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.coi.2025.102662_bib32","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.35365","volume":"130","author":"Bazarbachi","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.coi.2025.102662_bib33","doi-asserted-by":"crossref","first-page":"32.e1","DOI":"10.1016\/j.jtct.2024.07.017","article-title":"Combination of anti-thymocyte globulin with post-transplant cyclophosphamide for GVHD prophylaxis in patients undergoing haploidentical hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"31","author":"Luo","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.coi.2025.102662_bib34","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2020.06.026","article-title":"Timing of post-transplantation cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the acute leukemia working party of the European Society for Blood and Marrow Transplantation","volume":"26","author":"Ruggeri","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.coi.2025.102662_bib35","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00277-021-04439-6","article-title":"Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide","volume":"100","author":"Kurita","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.coi.2025.102662_bib36","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/jha2.962","article-title":"Combination of reduced post-transplant cyclophosphamide and early tacrolimus initiation increases the incidence of chronic graft-versus-host disease in human leukocyte antigen-haploidentical peripheral blood stem-cell transplantation","volume":"5","author":"Terao","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.coi.2025.102662_bib37","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.bbmt.2014.07.020","article-title":"Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation","volume":"20","author":"Solomon","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.coi.2025.102662_bib38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/sj.bmt.1705628","article-title":"Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells","volume":"39","author":"Coenen","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.coi.2025.102662_bib39","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.bbmt.2015.04.025","article-title":"Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells","volume":"21","author":"Cieri","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.coi.2025.102662_bib40","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1182\/blood.2021013054","article-title":"Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning","volume":"139","author":"McCurdy","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102662_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2025.102662_bib42","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.bbmt.2018.06.007","article-title":"Haploidentical Bone marrow transplantation with post-transplant cyclophosphamide\/bendamustine in pediatric and young adult patients with hematologic malignancies","volume":"24","author":"Katsanis","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.coi.2025.102662_bib43","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/bloodadvances.2023010545","article-title":"PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation","volume":"7","author":"Al-Homsi","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2025.102662_bib44","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/bloodadvances.2024015094","article-title":"A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept","volume":"9","author":"Koura","year":"2025","journal-title":"Blood Adv"},{"issue":"100 Suppl 3","key":"10.1016\/j.coi.2025.102662_bib45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ajh.27597","article-title":"Update in GVHD prophylaxis: novel pharmacologic and graft manipulation strategies","volume":"100","author":"Hexner","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.coi.2025.102662_bib46","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025029584","article-title":"\u00ad\u00ad\u00adRGI-2001 for the prophylaxis of acute graft-versus-host disease following allogeneic HCT","author":"DeFilipp","year":"2025","journal-title":"Blood"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:38:50Z","timestamp":1775032730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525001384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":46,"alternative-id":["S0952791525001384"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102662","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-transplant cyclophosphamide for\u00a0graft-versus-host disease prophylaxis: current status and optimization strategies","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102662","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102662"}}